secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0000950170-24-050887
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes Q1 2024 revenue $350.4M, GAAP net income $38.9M, LYBALVI sales up 50% YoY
--------------------------------------------------------------------------------

- Total revenues of $350.4M vs $287.6M in Q1 2023; GAAP net income from continuing ops $38.9M ($0.23 EPS) vs loss of $12.1M.
- LYBALVI net sales $57.0M (+50% YoY); VIVITROL $97.7M; ARISTADA $78.9M; royalty revenue $62.7M from J&J sublicense.
- Non-GAAP net income from continuing ops $76.2M vs $30.1M; cash & investments $807.8M, debt $290.1M.
- R&D expense $67.6M (+6%) driven by ALKS 2680; SG&A $179.7M (+7%) on LYBALVI DTC campaign.
- Company reiterates 2024 financial expectations; positive phase 1b data for ALKS 2680 in narcolepsy type 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017024050887/0000950170-24-050887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017024050887/alks-20240501.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-050887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer